Trial Profile
A Multiple Dose Study of Safety, Tolerability and Pharmacokinetics of ABT-126 in Elderly Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Nov 2010
Price :
$35
*
At a glance
- Drugs Nelonicline (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- 20 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 May 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
- 30 Mar 2009 New trial record